Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

NCT03290079 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors
Neuroendocrine Carcinoma
Neuroendocrine Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Lenvatinib

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]